companydata.dkcompanydata.dk

ASCENDIS PHARMA BONE DISEASES A/S: Financial statements 2014

CVR: 32323596

Source: annual report 2014, Danish Business Authority

01/01/2014 – 31/12/2014

ASCENDIS PHARMA BONE DISEASES A/S (CVR 32323596) has filed annual accounts for 2014. In 2014, the company reported a gross profit of EUR -1,220,383 and a net result of EUR -1,336,808 compared with DKK -4,115,409 the year before. Equity in the 2014 report amounted to EUR -1,660,625.

Gross Profit
EUR -1,220,383
Profit/Loss
EUR -1,336,808
Equity
EUR -1,660,625
Total Assets
EUR 615,467

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2014--1.2 mio. EUR-1.3 mio. EUR-1.7 mio. EUR-
2013--4.1 mio.-4.1 mio.-4 mio.-

Official annual report

View the official annual report directly on the page with a Pro subscription.

Screen every Danish company

Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.

Try company screening

Events in 2014

ASCENDIS PHARMA BONE DISEASES A/S: The 2013 annual report is outJun 3, 2014

ASCENDIS PHARMA BONE DISEASES A/S has published its annual report for 2013. Gross profit came to DKK -4,105,157, and the net result was DKK -4,115,409.

About ASCENDIS PHARMA BONE DISEASES A/S

ASCENDIS PHARMA BONE DISEASES A/S is a Danish company of the type Aktieselskab based in Hellerup, founded in 2012. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named ASCENDIS PHARMA OSTEOARTHRITIS DIVISION A/S and ASCENDIS PHARMA RHEUMATOLOGY DIVISION A/S. The management consists of Jan Møller Mikkelsen. The board consists of Michael Wolff Jensen (chair), Anni Lotte Kirstine Pedersen and Jan Møller Mikkelsen. The company is owned by ASCENDIS PHARMA A/S. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of EUR 229,581,000 and a net result of EUR 134,982,000 compared with EUR -139,088 the year before. Equity in the 2025 report amounted to EUR -372,183,000.

Source: annual report 2025, Danish Business Authority